74 patents
Page 2 of 4
Utility
High concentration formulations of adalimumab
25 Jan 22
The present invention relates to aqueous pharmaceutical compositions comprising a high concentration (i.e., greater than 50 milligrams per milliliter) of adalimumab (including antibody proteins considered or intended as “biosimilar” or “bio-better” variants of commercially available adalimumab) suitable for long-term storage, and methods of manufacture of the compositions; methods of their administration; and articles containing the same.
Mark Manning, Ryan Erik Holcomb
Filed: 28 Oct 16
Utility
PPAR-gamma AGONIST FOR TREATMENT OF BLOOD CANCERS
9 Dec 21
Christos Mantzoros
Filed: 18 Aug 17
Utility
Stable Aqueous Formulations of Natalizumab
21 Oct 21
Described herein is a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of natalizumab (optionally not subjected to prior lyophilization), a buffer effective to maintain the pH in the range from about 4.0 to about 7.0; and optionally, one or more surfactant{s), one or more amino acid(s), one or more sugar(s), one or more polyol(s), one or more chelating agent(s) (one or more polymer(s), one or more other stabilizing agent(s); and methods for making such a formulation; and methods of using such a formulation.
Mark Manning, Robert Walter Payne
Filed: 18 Jul 16
Utility
Etanercept formulations stabilized with metal ions
5 Oct 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 31 Oct 17
Utility
Etanercept formulations stabilized with amino acids
28 Sep 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions stabilized with an amino acid and suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 21 Mar 19
Utility
PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
16 Sep 21
Barbara Finck, David E. Weinstein, Sarita K. Jain
Filed: 3 Apr 18
Utility
Method of filling a container with no headspace
27 Jul 21
The present invention is directed to methods for filling a container wherein the filled container has no headspace.
John Ogez, Jun Liu, Wenchang Ji, Patrick Daniel Begley, Isaias Prado, Mark Manning
Filed: 20 Apr 17
Utility
Etanercept formulations stabilized with sodium chloride
11 May 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 28 Jun 19
Utility
Method of manufacturing a protein by perfusion in media with a low amino acid concentration
11 May 21
Perfusion media are disclosed providing excellent cell density, titer and product quality for production of a therapeutic protein in a perfusion process.
Ela Puchacz, James Russell Grove
Filed: 13 Aug 18
Utility
Correctly folded etanercept in high purity and excellent yield
11 May 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 29 Sep 17
Utility
Method of reducing formation of etanercept aggregates or fragments
27 Apr 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 14 Jun 19
Utility
Correctly folded etanercept composition
13 Apr 21
Production of etanercept using perfusion methods achieves attractive yields of properly folded protein.
Ela Puchacz, James Russell Grove
Filed: 30 Jun 15
Utility
Correctly folded etanercept in high purity and excellent yield
23 Mar 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 17 Jun 19
Utility
Correctly folded etanercept in high purity and excellent yield
23 Mar 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 17 Jun 19
Utility
Correctly folded etanercept in high purity and excellent yield
23 Mar 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 17 Jun 19
Utility
Correctly folded etanercept in high purity and excellent yield
16 Mar 21
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu Arakawa, Douglas Farrar
Filed: 17 Jun 19
Utility
Etanercept Formulations Exhibiting Marked Reduction In Sub-visible Particles
14 Jan 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, with substantial reduction in sub-visible particles, and methods of manufacture of these compositions, methods of administration, and articles of manufacture.
Mark MANNING, Brian MURPHY, Douglas FARRAR, Alan HERMAN
Filed: 28 Sep 20
Utility
Stable aqueous etanercept composition
12 Jan 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 14 Jun 19
Utility
Etanercept Formulations Stabilized with Xylitol
30 Dec 20
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark MANNING, Brian Murphy
Filed: 13 Sep 20
Utility
Methods for the Treatment of Nonalcoholic Fatty Liver Disease And/or Lipodystrophy
9 Dec 20
The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARγ agonist, INT131 and optionally vitamin E or compositions thereof.
Christos Mantzoros
Filed: 24 Jun 20